NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.
AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...
Also Read: FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients The U.K. Treasury, under the direction of Rachel Reeves, is reportedly considering ...
The illegal importation case may not stop there, AstraZeneca CEO Pascal Soriot warned. “It’s possible that a similar issue is raised around Enhertu,” Soriot told reporters Thursday.
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...
Also Read: AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth In the trial, Enhertu showed a 36% reduction in the risk of disease progression or death versus chemotherapy ...
Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3 ...
New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...
Astrazeneca shares rose nearly 1% following unexpectedly positive interim results from a Phase III trial of its breast cancer drug Camizestrant. The study revealed that patients with hormone ...